[Recent advances on the use of erythropoietin in oncology].
The Standards, Options and Recommendations on the use of erythropoietin in cancer patients are recalled. The recent literature is analysed and allows some further comments to the SOR. Medico-economic aspects, new schedules of administration, extra-hematologic virtues of erythropoietin and its impact on cancer outcomes are debated.
Spaëth
Dominique
D
Département d'oncologie médicale, Centre Alexis-Vautrin, avenue de Bourgogne, 54511 Vandoeuvre-lès-Nancy Cedex. spaeth@nancy.fnclcc.fr
D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects; D002648:Child; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008495:Medical Oncology / Q000592:standards; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins
D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa